Weekly cannabis use linked to entry symptoms, not later Long COVID

Associations between substance use and symptomatic Long COVID in the Researching COVID to Enhance Recovery (RECOVER)-adult cohort study.

Addiction (Abingdon, England) • • Relevant
🤖

AI Summary

This prospective cohort study examined whether tobacco, cannabis, and binge alcohol use in the year before SARS-CoV-2 infection was associated with symptomatic Long COVID. It included 9,477 adults across 83 U.S. clinical sites and assessed both symptoms at study entry and new symptomatic Long COVID over 12 months among participants who did not have it at entry.

At study entry, weekly or more cannabis use was associated with higher odds of symptomatic Long COVID than no use (adjusted odds ratio 1.23; 95% CI 1.00–1.52), while monthly or less cannabis use was not associated. Cannabis use was not statistically significantly associated with developing symptomatic Long COVID during follow-up. Weekly or more tobacco use was associated with higher odds at entry and during follow-up; weekly or more binge alcohol use was associated with lower odds at entry but not at follow-up. These are observational associations, not evidence that substance use caused or prevented symptoms. This abstract-based summary cannot establish causation, and it does not show that the reported associations represent clinically meaningful effects.

💡 Key Findings

1
In this prospective observational cohort, weekly or more cannabis use was associated with higher odds of symptomatic Long COVID at study entry compared with no use (adjusted odds ratio 1.23; 95% CI 1.00–1.52).
Good
75%
2
Cannabis use was not statistically significantly associated with developing symptomatic Long COVID over 12 months among participants who did not have it at study entry.
High
80%
3
Monthly or less cannabis use was not associated with symptomatic Long COVID at study entry.
High
80%
4
Weekly or more tobacco use was associated with higher odds of symptomatic Long COVID at entry and during follow-up; weekly or more binge alcohol use was associated with lower odds at entry but not significantly associated during follow-up.
High
80%

📄 Original Abstract

AIMS: To determine whether frequency of tobacco, cannabis and binge alcohol use in the 12 months prior to SARS-CoV-2 test result or COVID-19 symptom onset is associated with (1) presence of symptomatic Long COVID at study entry and (2) development of symptomatic Long COVID over 12 months of follow-up, among those without Long COVID at study entry. DESIGN: Prospective cohort study with cross-sectional and longitudinal components. SETTING: Multi-site study conducted across 83 clinical sites in the United States. PARTICIPANTS: A total of 9477 adults enrolled between October 2021 and July 2024 (median age 43 years; 74% female). MEASUREMENTS: Self-reported frequency of tobacco product, cannabis and binge alcohol use in the 12 months prior to SARS-CoV-2 test infection (never, monthly or less, weekly or none). Symptomatic Long COVID was defined using the Researching COVID to Enhance Recovery (RECOVER)-Adult Long COVID Research Index, with scores ≥ 11 classified as symptomatic Long COVID and lower scores classified as indeterminate. Covariates included sociodemographic characteristics, clinical comorbidities and COVID-19 related factors. RESULTS: At study entry 20% of participants met criteria for symptomatic Long COVID. In the 12 months preceding infection, 14%, 21% and 38% reported any tobacco product, cannabis or binge alcohol use. At study entry, compared with no use, weekly or more tobacco use was associated with higher odds of symptomatic Long COVID [adjusted odds ratio (aOR) = 1.37, 95% confidence interval (CI) = 1.13-1.67]; weekly or more cannabis use was associated with higher odds of symptomatic Long COVID (aOR = 1.23, 95% CI = 1.00-1.52); and weekly or more binge alcohol use was associated with lower odds (aOR = 0.73, 95% CI = 0.58-0.91) of symptomatic Long COVID. Monthly or less use of any substance was not associated with symptomatic Long COVID at study entry. Among participants without symptomatic Long COVID at study entry, weekly or more tobacco use, compared with no use, was associated with higher odds of developing symptomatic Long COVID over 12 months of follow-up (aOR = 1.29, 95% CI = 1.03-1.62). Neither cannabis nor binge alcohol use was statistically significantly associated with symptomatic Long COVID at 12-month follow-up. SUMMARY: Among adult participants of the Researching COVID to Enhance Recovery (RECOVER) study, weekly or more tobacco use in the 12 months prior to SARS-CoV-2 infection was associated with higher odds of symptomatic Long COVID at study entry and at 12 months among participants who did not meet criteria for symptomatic Long COVID at study entry. Weekly or more cannabis use was associated with higher odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months. Weekly or more binge alcohol use was associated with lower odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.